Talk:Hydroxynorketamine

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Hydroxynorketamine.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Legal status[edit]

Is hydroxynorketamine a scheduled substance (more technically, are any of the hydroxynorketamines scheduled substances) in any jurisdiction, and if so, what jurisdictions assign it to what schedules? Antediluvian67 (talk) 23:26, 13 February 2017 (UTC)[reply]

Regarding "Ketamine and metabolites at the NMDAR"[edit]

Drawing from Suzuki K. et al.,(2017), the article states: "a June 2017 study found that (2R,6R)-HNK does in fact block the NMDA receptor, similarly to ketamine.", suggesting that the antidepressant activity of (2R,6R)-HNK may be NMDAR dependent. Significant NMDAR antagonism by this compound was only observed a dosage of 50μM^[1], despite the presence of antidepressant effects at only 10μM ^[2]. OllyTheBug (talk) 01:35, 6 March 2019 (UTC)[reply]

References

^ Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM (2017). "Effects of a ketamine metabolite on synaptic NMDAR function". Nature. 546 (7659): E1–E3. doi:10.1038/nature22084. PMID 28640258.
^ Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Georgiou, Polymnia; Fischell, Jonathan; Elmer, Greg I.; Alkondon, Manickavasagom; Yuan, Peixiong; Pribut, Heather J.; Singh, Nagendra S.; Dossou, Katina S. S.; Fang, Yuhong; Huang, Xi-Ping; Mayo, Cheryl L.; Wainer, Irving W.; Albuquerque, Edson X.; Thompson, Scott M.; Thomas, Craig J.; Zarate Jr, Carlos A.; Gould, Todd D. (2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533: 481–486. doi:10.1038/nature17998. ISSN 0028-0836. PMC 4922311. PMID 27144355.

[pmid28640258-1] Suzuki K, Nosyreva E, Hunt KW, Kavalali ET, Monteggia LM (2017). "Effects of a ketamine metabolite on synaptic NMDAR function". Nature. 546 (7659): E1–E3. doi:10.1038/nature22084. PMID 28640258.

[ZanosMoaddel2016-2] Zanos, Panos; Moaddel, Ruin; Morris, Patrick J.; Georgiou, Polymnia; Fischell, Jonathan; Elmer, Greg I.; Alkondon, Manickavasagom; Yuan, Peixiong; Pribut, Heather J.; Singh, Nagendra S.; Dossou, Katina S. S.; Fang, Yuhong; Huang, Xi-Ping; Mayo, Cheryl L.; Wainer, Irving W.; Albuquerque, Edson X.; Thompson, Scott M.; Thomas, Craig J.; Zarate Jr, Carlos A.; Gould, Todd D. (2016). "NMDAR inhibition-independent antidepressant actions of ketamine metabolites". Nature. 533: 481–486. doi:10.1038/nature17998. ISSN 0028-0836. PMC 4922311. PMID 27144355.

[1]

[2]